Purpose Of Review: Uncertainties exist regarding the optimal treatment for vancomycin-resistant enterococcal (VRE) bloodstream infections, particularly in settings in which ampicillin cannot be used.
Recent Findings: Quinupristin-dalfopristin, linezolid, and daptomycin, all approved between 1999 and 2003, represent the mainstays of therapy for VRE bacteremia, although only linezolid has been specifically approved by the United States Food and Drug Administration for this indication. The main objective of this review is to compare the relative efficacies, dosing strategies, and side-effect profiles of quinupristin-dalfopristin, linezolid, and daptomycin for VRE bacteremia in the pediatric population. A brief description of recently approved broad-spectrum Gram-positive agents that may have a role in the management of VRE bacteremia in upcoming years is also provided.
Summary: Linezolid, despite its bacteriostatic activity against VRE, may be the most versatile of the available drugs. It has activity against both Enterococcus faecalis and E. faecium, can be administered orally, and resistance appears to be less of a concern with linezolid compared with the other agents. Additionally, the results of two recent meta-analyses demonstrate more favorable outcomes with linezolid compared with daptomycin for the treatment of VRE bacteremia. The clinical pharmacokinetics of linezolid have been well described in children. The most notable concern with linezolid, however, is toxicities associated with prolonged use. Until more prospective data are available, we favor linezolid as first-line therapy for the treatment of VRE bacteremia in children.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/QCO.0000000000000115 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Factors associated with multidrug-resistant organism (MDRO) mortality: an analysis from the national surveillance of multidrug-resistant organism, 2018-2022.
BMC Infect Dis
January 2025
Department of Public Health Medicine, Faculty of Medicine, National University of Malaysia, Federal Territory of Kuala Lumpur, Jalan Yaacob Latif, Bandar Tun Razak, 56000, Cheras, Malaysia.
Introduction: Antimicrobial resistance is a global issue, with the World Health Organization identifying it as one of the greatest threats to public health, with an estimated 4.95 million deaths linked to bacterial AMR in 2019. Our study aimed to determine the prevalence of mortality among multidrug-resistant organism (MDRO)-infected patients in state hospitals and major specialist hospitals and to identify risk factors that could be associated with mortality outcomes.
View Article and Find Full Text PDFAntimicrobial Resistance Profile of Enterococcal Isolates From Clinical Specimens at a Tertiary Care Hospital in Western Maharashtra, India.
Cureus
November 2024
Department of Microbiology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth (Deemed to Be University), Karad, IND.
Background , once benign intestinal flora, has transformed into formidable nosocomial pathogens as a result of the accelerated emergence of antibiotic resistance represents a major global health challenge, particularly within hospital settings. has grown more prevalent in nosocomial infections, such as urinary tract infections (UTIs), surgical site infections (SSIs) and bacteremia. The potential emergence of vancomycin-resistant (VRE) strains further complicates treatment choices for multi-drug resistant (MDR) infections.
View Article and Find Full Text PDFRectal colonization with multidrug-resistant organisms and risk for bloodstream infection among high-risk Greek patients.
Eur J Clin Microbiol Infect Dis
November 2024
Laboratory of Clinical Microbiology, School of Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Background: Studies link multidrug-resistant organism (MDRO) rectal colonization to increased infection risk, data from Greece, a country with high rates of MDRO, are limited.
Methods: We assessed bloodstream infection (BSI) risk following rectal colonization by MDROs across three Greek hospitals (2019-2022).
Results: Of 4,370 inpatients, 31.
Management of Recurrent Vancomycin-resistant Bacteremia With Oritavancin: A Case Report.
In Vivo
October 2024
Department of Internal and Hospital Medicine, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, U.S.A.
Background/aim: Vancomycin-resistant Enterococcus causes significant morbidity, mortality, and excess healthcare costs when compared to vancomycin-susceptible isolates. Patients with hematological malignancies, especially those who undergo hematopoietic stem cell transplantation, are at a particularly high risk for infections with vancomycin-resistant Enterococcus, with mortality ranging from 40-100%. Linezolid and daptomycin are the two most commonly used antibiotics for treatment of vancomycin-resistant enterococcal infections, however, there has been recent emergence of resistance to these drugs as well.
View Article and Find Full Text PDFGlobal landscape of vancomycin-resistant enterococci in hematopoietic stem-cell transplantation patients: a systematic review and meta-analysis.
BMC Infect Dis
October 2024
Infectious Diseases Research Center, AJA University of Medical Sciences, Tehran, Iran.
Background: One of the main risks of infection after hematopoietic stem cell transplantation (HSCT) is infection by gram-positive bacteria, including vancomycin-resistant enterococci (VRE). Based on the format of a global review and meta-analysis study, this study aims to investigate the incidence of VRE bloodstream infection (BSI) after HSCT in colonized individuals.
Methods: The keywords of the systematic search included vancomycin-resistant enterococci and HSCT.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!